Axiom Investors LLC DE Sells 473,023 Shares of Danaher Corporation $DHR

Key Points

• Axiom Investors LLC DE reduced its holdings in Danaher Corporation by 66.0% during the first quarter, selling 473,023 shares and owning 243,553 shares valued at approximately $49.93 million.
• Other institutional investors, including GHP Investment Advisors Inc. and Sierra Ocean LLC, have increased their holdings in Danaher, indicating a mixed but overall strong institutional interest in the company.
• Danaher recently reported earnings per share (EPS) of $1.80 for the last quarter, surpassing analyst estimates, and its stock has a consensus rating of "Moderate Buy" from 17 analysts.

Axiom Investors LLC DE decreased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 66.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,553 shares of the conglomerate's stock after selling 473,023 shares during the period. Axiom Investors LLC DE's holdings in Danaher were worth $49,928,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the period. Bank of New York Mellon Corp grew its holdings in Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the period. Northern Trust Corp boosted its position in Danaher by 14.3% during the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock worth $1,821,477,000 after purchasing an additional 992,594 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Danaher by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after purchasing an additional 579,046 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on DHR shares. Evercore ISI cut their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research report on Friday, July 11th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Finally, Barclays reissued an "overweight" rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Price Performance

Shares of NYSE:DHR traded down $1.29 during midday trading on Wednesday, hitting $204.96. The stock had a trading volume of 2,503,235 shares, compared to its average volume of 4,195,627. The company's 50-day moving average price is $201.02 and its 200-day moving average price is $199.43. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $146.76 billion, a P/E ratio of 43.61, a price-to-earnings-growth ratio of 2.90 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the business posted $1.72 EPS. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 11.20% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.